Why the study?
Does transcatheter left atrial appendage occlusion reduce stroke rates compared to warfarin in patients with atrial fibrillation?
Does transcatheter left atrial appendage occlusion reduce stroke rates compared to warfarin in patients with atrial fibrillation?
Transcatheter left atrial appendage occlusion is a feasible and noninferior alternative to warfarin for stroke prevention in atrial fibrillation, though optimal patient selection requires further study.
Answers are grounded in this paper and cite their sources.
May support LAA occlusion as warfarin alternative in AF; leaves open optimal patient selection.
For patients with atrial fibrillation, successful warfarin therapy is difficult in clinical practice. Thus, it seems logical to find alternative therapies to chronic anticoagulation. The major source of thromboembolism in such patients is the left atrial appendage, and occlusion of the appendage with transcatheter devices is feasible, reduces anticipated stroke rates and has been found to be noninferior to warfarin therapy in a large, randomized trial. Trials with new devices are planned. In light of the current data, how patients with atrial fibrillation who need warfarin, who are either at risk with anticoagulation or who desire not to undergo warfarin therapy should best be treated is not clear. Hopefully, with more experience and longer term outcomes of clinical trials, these issues will finally be laid to rest.
No takes yet. Share an insight, caveat, or question.
Peter C. Block (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: